Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupGastroenterologic OncologyradiotherapyDiseaseAnal CarcinomaSubgroupICD10C21.-C21.0C21.1C21.2C21.8MeSHAnus NeoplasmsSequenceChemotherapyChemo-substanceCapecitabineFluorouracilMitomycinChemo-substanceCapecitabineFluorouracilMitomycinChemo-substanceCapecitabineFluorouracilMitomycinChemo-substanceCapecitabineFluorouracilMitomycinNo. Substances2 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionGranisetronSupportive substanceBalanced Crystalloid SolutionGranisetronSupportive substanceBalanced Crystalloid SolutionGranisetronSupportive substanceBalanced Crystalloid SolutionGranisetronNo. Substances2Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineTherapy phaseTherapy intentioncurativeRisksEmetogenicity (MASCC/ESMO)Febrile NeutropeniaRadiation Dermatitis only studiesPublicationAuthorAjani JAThind GDiseasePlattenepithel- , Basalzell- oder kloakogenes Anal-Ca, T2-T4, jedes N, M0Plattenepithel- oder kloakogenes Anal-Ca, Stadium I-III, ECOG 0-2OriginDepart. of Gastroint. Med. Oncology, Anderson Cancer Center, Texas, USA. Intergroup RTOG 98-11 StudieThe British Columbia Cancer AgencyProtocols in Revision 2 protocols foundProtocols under revision.Capecitabine 825 / Mitomycin 12 / Radiation, Anal Carcinoma (PID481 V1.1)Fluorouracil 1000 / Mitomycin 10 / Radiation, Anal Carcinoma (PID480 V1.1)
